Navigation Links
Active Biotech presents new pre-clinical data for the 57-57 project,at the 8th World Congress on Inflammation

LUND, Sweden, June 18, 2007-Active Biotech (OMX Nordic: ACTI) has presented pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation ( held in Copenhagen June 16-20*.

"The results strengthen the further clinical development of 57-57 for the treatment of SLE and show the possibility to reduce the use of steroids. Phase II clinical trials are planned to be initiated before year end", commented Sven Andréasson, President & CEO Active Biotech.

The new pre-clinical data presented show that 57-57, in an experimental model of the disease systemic lupus erythematosus (SLE), can replace prednisolone, an anti-inflammatory corticosteroid widely used in a broad range of different inflammatory diseases, among them SLE.

Several symptoms commonly associated with SLE, such as hematuria (blood in the urine) and glomerulonephritis (inflammation in the kidneys) could be significantly reduced when combining 57-57 and a lower dose of steroid.

Lund, June 18, 2007

Active Biotech AB (Publ)

Sven Andréasson President & CEO

About SLE and 57-57 Systematic Lupus Erythematosus (SLE) is a disease of the connective tissues that can cause inflammation and damage to the connective tissue in many different organs. The disease, which progresses in "flare-ups" interspersed with relatively symptom-free periods, primarily affects women of child-bearing age. Progress and symptoms of the disease vary widely, depending on the organs affected. Without treatment, SLE can be life-threatening. Active Biotech has decided to estimate the market conservatively at 1,000,000 patients in the US and Europe. The market potential for the SLE indication is estimated at approximately USD 6 billion.

The clinical program for the 57-57 project with the main indication SLE is proceedi ng according to plan. This study comprises patients with SLE or rheumatoid arthritis (RA). This is a multi-center study and is being conducted at three hospitals in Sweden - the Karolinska University Hospital in Stockholm, Uppsala University Hospital and Lund University Hospital, in addition to clinics in Russia. Phase II studies are planned to start during 2007.

57-57 has been given the international generic name (INN) paquinimod by the World Health Organization (WHO).

* For further information and to take part of the complete poster "Steroid Sparing Effect of Paquinimod (ABR-215757) in Disease Development of Experimental Lupus in MRLlpr/lpr Mice", please visit .

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB (org. no. 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 20 50


Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Gentiums Defibrotide Seen as Active in Multiple Myeloma
3. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
4. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
5. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
6. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
10. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
11. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
Breaking Medicine Technology:
(Date:11/26/2015)... Omaha, NE (PRWEB) , ... November 26, 2015 , ... ... careers searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical ... top during the month of October 2015 among those searching for healthcare jobs through ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel ... self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with ... work with any font, giving users limitless opportunities to stylize and create designs ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the ... several models of traditional and far-infrared saunas. , For traditional saunas, Finnleo ... most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
Breaking Medicine News(10 mins):